首页> 外文期刊>Annals of vascular surgery >The effect of beta-blocker dosing strategy on regulation of perioperative heart rate and clinical outcomes in patients undergoing vascular surgery: a randomized comparison
【24h】

The effect of beta-blocker dosing strategy on regulation of perioperative heart rate and clinical outcomes in patients undergoing vascular surgery: a randomized comparison

机译:β受体阻滞剂给药策略对血管手术患者围手术期心率和临床结局的调节作用:随机比较

获取原文
获取原文并翻译 | 示例
           

摘要

The optimal dosing strategy for perioperative beta-blockers to safely achieve recommended target heart rates (HRs) by current guidelines is not well defined. An HR-titrated perioperative beta-blocker dosing regimen versus a fixed-dose regimen was assessed by clinical outcomes, postoperative heart rate, and beta-blocker-related complications. Patients (n = 64) scheduled to undergo moderate- to high-risk vascular surgery and without contraindications to beta-blockade were randomized to either a fixed-dose or HR-titrated beta-blocker dosing schedule. Clinical outcomes and HRs were followed immediately preoperatively to 24 hr postoperatively. A difference in mean HR between the two dosing arms was significant immediately postoperatively (70.1 vs. 58.2 bpm for fixed dose and HR-titrated arms, respectively; p = 0.012) but at no other time points. However, the HR-titrated strategy led to a significant reduction in the percentage of HR measurements >80 bpm (34.5% vs. 16.1%, p < 0.001) and to a significant reduction in absolute HR change (17.5 vs. 22.5 bpm, p = 0.034). There were no significant differences in the occurrence of asymptomatic hypotension between the two study arms, and no beta-blocker-related adverse events occurred in either study arm. An aggressive, HR-titrated perioperative beta-blocker dosing strategy was associated with more consistent maintenance of postoperative HRs within the range recommended by current guidelines and did not result in increased drug-related adverse events. The question of what is the best perioperative beta-blocker dosing regimen warrants further evaluation in a large-scale clinical trial.
机译:围手术期β受体阻滞剂安全地达到当前指南推荐的目标心率(HR)的最佳剂量策略尚未明确定义。通过临床结局,术后心率和与β受体阻滞剂相关的并发症评估了HR调整的围手术期β受体阻滞剂给药方案与固定剂量方案之间的关系。计划接受中度至高风险血管手术且无β受体阻滞禁忌症的患者(n = 64)被随机分配至固定剂量或HR滴定的β受体阻滞剂给药方案。术前至术后24小时随访临床结局和HR。术后两个给药臂之间的平均HR差异显着(固定剂量和HR滴定臂分别为70.1和58.2 bpm; p = 0.012),但在其他时间点均无。但是,以HR调整的策略导致HR测量值> 80 bpm的百分比显着降低(34.5%比16.1%,p <0.001),并且绝对HR变化显着降低(17.5 vs. 22.5 bpm,p) = 0.034)。两个研究组之间无症状性低血压的发生率无显着差异,两个研究组中均未发生与β受体阻滞剂相关的不良事件。积极的,HR调整的围手术期β受体阻滞剂给药策略与在当前指南建议的范围内更一致地维持术后HR有关,并且不会导致与药物相关的不良事件增加。什么是围手术期最佳的β-受体阻滞剂最佳给药方案的问题值得在大规模临床试验中进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号